Sadaf Qureshi
Biographic Data
| ID | 8210889 |
|---|---|
| NAME | Sadaf Qureshi |
| GIVEN NAMES | Sadaf |
| FAMILY NAME | Qureshi |
| SIGNATURE | QURESHI S |
| AFFILIATIONS | Derbyshire County Council |
| ORCID | 0000-0002-2836-6712 |
| VERIFIED | Yes |
| TOTAL WORKS | 4 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 4 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2020 |
| LATEST PUBLICATION YEAR | 2023 |
| H-INDEX | 0 |
Advancing oncology drug therapies for sub-Saharan Africa
Cancer incidence is rising across sub-Saharan Africa (SSA), and is often characterized by late-stage presentation, early age of onset and poor survival. While a number of oncology drugs are now improving the length and quality of life for cancer patients in high-income countries, significant disparities in access to a range of oncology therapeutics exist for SSA. A number of challenges to drug access such as drug costs, lack of infrastructure and…
When You Smile at Misfortune
I stand, like 1 of 12 soldiers, lined up in a long hallway with 6 doors on each side. A bell rings signaling the beginning of the exercise, and each soldier shuffles dutifully toward a folder clipped to the door in front. It is an exercise we have all been through before, but the nervous energy still emanates from each of us. We knock on our doors, almost in unison, and enter with feigned confidence. My third-year observed standardized clinical e…
Seeing Is Believing
Specialist recommendation for chemoprevention medications in patients at familial risk of breast cancer
In England, the National Institute for Health and Care Excellence guideline for familial breast cancer recommends chemoprevention for women at high and moderate familial risk of breast cancer. However, prescribing of chemoprevention has not improved since the introduction of the guideline in 2013. The study aims to identify the current practice, in England, of familial cancer specialists offering chemoprevention and recommending prescribing in pr…
No prominent works on this page.
Seeing Is Believing
Specialist recommendation for chemoprevention medications in patients at familial risk of breast cancer
In England, the National Institute for Health and Care Excellence guideline for familial breast cancer recommends chemoprevention for women at high and moderate familial risk of breast cancer. However, prescribing of chemoprevention has not improved since the introduction of the guideline in 2013. The study aims to identify the current practice, in England, of familial cancer specialists offering chemoprevention and recommending prescribing in pr…
When You Smile at Misfortune
I stand, like 1 of 12 soldiers, lined up in a long hallway with 6 doors on each side. A bell rings signaling the beginning of the exercise, and each soldier shuffles dutifully toward a folder clipped to the door in front. It is an exercise we have all been through before, but the nervous energy still emanates from each of us. We knock on our doors, almost in unison, and enter with feigned confidence. My third-year observed standardized clinical e…
Advancing oncology drug therapies for sub-Saharan Africa
Cancer incidence is rising across sub-Saharan Africa (SSA), and is often characterized by late-stage presentation, early age of onset and poor survival. While a number of oncology drugs are now improving the length and quality of life for cancer patients in high-income countries, significant disparities in access to a range of oncology therapeutics exist for SSA. A number of challenges to drug access such as drug costs, lack of infrastructure and…
Medicine (4 works) · Cancer (2 works) · Internal Medicine (2 works) · Psychology (2 works) · Aesthetics (1 work) · Art (1 work) · BRCA gene mutations in cancer (1 work) · Breast cancer (1 work) · Cancer drugs (1 work) · Cancer Genomics and Diagnostics (1 work)